Cargando…
Fondaparinux and bleeding risk in COVID-19: unsolved question
Autores principales: | Russo, Vincenzo, Proietti, Riccardo, Lodigiani, Corrado, Di Micco, Pierpaolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870442/ https://www.ncbi.nlm.nih.gov/pubmed/33592530 http://dx.doi.org/10.1016/j.thromres.2021.01.025 |
Ejemplares similares
-
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin
por: Prandoni, Paolo, et al.
Publicado: (2020) -
Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate
por: Di Micco, Pierpaolo, et al.
Publicado: (2020) -
Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
por: Cardillo, Giuseppe, et al.
Publicado: (2021) -
Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study
por: Russo, Vincenzo, et al.
Publicado: (2020) -
Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome
por: Scudiero, Fernando, et al.
Publicado: (2021)